ArticleJournal of oral and maxillofacial pathology : JOMFP
Immunohistochemical expression of podoplanin as a myoepithelial cell marker in pleomorphic adenoma.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePleomorphic adenoma (PA) is the most common benign salivary gland tumor with salivary gland excision as the treatment of choice; however, recurrences after parotidectomy have been reported. The current study is aimed at evaluating podoplanin expression in PA as a myoepithelial (ME) cell marker and its role in estimating the prognosis and outcome of the tumors by correlating it with various clinical and histological parameters. MATERIALS AND
methodsA total of 10 paraffin-embedded specimens of histologically diagnosed PA with clinical records of the patients were retrieved and the slides were then stained using hematoxylin and eosin staining and were then immunohistochemically stained with podoplanin.
resultsThe study revealed the specificity of podoplanin as a differential marker for ME cells.
conclusionAlthough the study revealed the specificity of podoplanin as a differential marker for ME cells, additional markers to overcome the limitations of podoplanin which will predict the biologic behavior (biologic behavior of the tumor) the tumor with respect to parameters such as age, gender and site of the tumor are required. Furthermore, a larger sample size is required to validate the findings in our data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.